Law Office Of Brodsky & Smith, LLC Announces Investigation Of IntegraMed America, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of IntegraMed America, Inc. (“IntegraMed” or the “Company”) (Nasdaq- INMD) relating to the proposed acquisition by Sagard Capital Partners. (“Sagrad”).

Under the terms of the transaction, IntegraMed shareholders will receive $14.05 in cash for each share of IntegraMed stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of IntegraMed for not acting in the Company’s shareholders' best interests in connection with the sale process to Sagrad. The transaction will not result in a substantial premium above the $13.50 that IntegraMed stock traded at on April 16, 2012 and is below a $17.00 analyst target price for IntegraMed stock.

If you own shares of IntegraMed stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com visiting http://brodsky-smith.com/435-inmd-integramed-america-inc.html, or by calling toll free 877-LEGAL-90.

Copyright Business Wire 2010

If you liked this article you might like

IntegraMed America Stock Soars (INMD)

IntegraMed America's CEO Discusses Q1 2012 Results - Earnings Call Transcript

IntegraMed's CEO Discusses Q4 2011 Results - Earnings Call Transcript

IntegraMed America's CEO Presents At Oppenheimer Healthcare Conference - Presentation Transcript

IntegraMed America's CEO Presents At Oppenheimer Healthcare Conference - Presentation Transcript

IntegraMed America Presentation At Oppenheimer Healthcare Conference - Transcript

IntegraMed America Presentation At Oppenheimer Healthcare Conference - Transcript